Glenn D Francis
Dr Glenn Francis graduated from the University of Queensland in 1984 (MBBS Hons) and subsequently trained in general pathology. Following completion of his training in 1991, he began work in a private pathology laboratory and established a number of new private laboratories in Central Queensland. Dr Francis developed an interest in breast and molecular pathology and became Convener of the RCPA Immunohistochemistry Quality Assurance Program (RCPA QAP Pty Ltd) in 2001. In 2002, he relocated to the Gold Coast and was appointed Pathologist in charge of the Gold Coast and Northern Rivers region in a private pathology laboratory. In 2005 he was appointed Director of Pathology Princess Alexandra Hospital Brisbane and established the Molecular and Clinical Pathology Research Laboratory in 2008. In 2011 he was appointed as Medical Director Pathology Queensland Central Laboratory (Royal Brisbane, Women's and Children's Hospitals) and initiated the molecular testing program for the RCPA QAP for mutations in EGFR, BRAF and KRAS. In late 2013 he returned to private pathology practice. He routinely reports molecular diagnostic pathology including next generation sequencing of somatic mutations in cancer using multi-gene panels and inherited disease. His current role also includes the oversight and reporting of NIPS in a private diagnostic molecular pathology laboratory, Genomics For Life. In 2016, Dr Francis commenced as Director Pathology Melbourne Health, Royal Melbourne Hospital. Dr Francis has a special interest in molecular pathology and personalised medicine. His current appointments include Adjunct Associate Professor Griffith University, President Australasian Immunohistochemistry Society, Molecular Pathology Advisory Board, EGFR IHC Expert Panel, RCPA Tissue Banking Working Party, Assessor for the National Association of Testing Authorities, RCPA General Pathology Advisory Committee, RCPA Genetic Pathology Advisory Committee, RCPA Cancer Services Advisory Committee and MSAC Expert Standing Panel. His current research activities include prognostic biomarkers in breast cancer, molecular biology, diagnostic oncology, next generation sequencing, neural network applications in pathology, immunohistochemistry and in-situ hybridization and he has recently completed a PhD. Collaborative research is being performed in conjunction with the University of Queensland and The Garvan Institute.
Abstracts this author is presenting: